CAS NO: | 32619-42-4 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Molecular Weight (MW) | 540.51 |
---|---|
Formula | C25H32O13 |
CAS No. | 32619-42-4 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 100 mg/mL (185.0 mM) |
Water: 100 mg/mL (185.0 mM) | |
Ethanol: 100 mg/mL (185.0 mM) | |
Solubility (In vivo) | PBS: 30mg/mL |
Synonyms | Methyl (4S,5E,6S)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-ethylidene-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate |
In Vitro | In vitro activity: In both J774A.1 cells and primary mouse macrophages, Oleuropein increases LPS-induced NO production. Oleuropein prevents oxidative myocardial injury induced by ischemia and reperfusion. In TF-1a; 786-O, T-47D, RPMI-7951, LoVo, and NL-Fib cells, Oleuropein inhibits cell proliferation and migration. |
---|---|
In Vivo | In swiss albino mice that spontaneously develop soft tissue sarcomas, Oleuropein (i.p. or p.o.) completely regresses tumors. In rats, Oleuropein (40 mg/kg, p.o.) protects from cardiac remodeling process after isoproterenol-induced myocardial infarction through inhibiting angiotensin-converting enzyme activity. |
Animal model | Swiss albino mice that spontaneously develops soft tissue sarcomas |
Formulation & Dosage | Dissolved in PBS; 50 μg/mouse; i.p. or p.o. administration |
References | Life Sci. 1998;62(6):541-6; Biochem Biophys Res Commun. 2005 Sep 2;334(3):769-78. |